- In December, a vaccine from Merck (NYSE:MRK) and NewLink Genetics (NASDAQ:NLNK) was declared to be 100% effective at preventing people from contracting Ebola, but there are questions about that claim.
- Scientists from the esteemed U.S. National Academy of Medicine have challenged the methodology of the drugmakers, concluding their vaccine "most likely provides some protection to recipients" but that protection "could in reality be quite low."
Ebola vaccine faces questions
Recommended For You
About MRK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRK | - | - |
Merck & Co., Inc. |